

Index

- Acetylcholine, 44
- Acute disseminated encephalomyelitis (ADEM), 338
- Acute phase response in Schizophrenia
 - haptoglobins, 478
- Adaptive immune response
 - cell-mediated immune response, 271–274
 - humoral immune response, 274, 275
- Adenoviral capsid proteins, 272
- Adenoviral vectors and immune responses, 268
- Adenoviruses, 267
- Adjuvant-induced arthritis, 85
- Adrenergic receptor(s), 62, 64, 66, 67, 73, 76
 - alpha-adrenergic receptor, 93
 - beta-adrenergic receptor, 93
 - cytokine production, 85, 91, 93, 95, 98, 100, 102, 105–111
 - immune cell trafficking, 91
 - immune function in vivo, 85–87, 89
 - inflammation, 104, 105
 - lymphocyte responses, 89
 - monokine production, 91–94
 - natural killer cell activity, 90
- α -Adrenergic receptor, 64, 66, 93
- β -Adrenergic receptor, 66, 67, 73–75, 93
- β -Adrenergic receptor density, 74
- Adrenocorticotropin (ACTH), 39, 40, 42, 44, 45, 48–50, 52
- Age, 132, 142
- Allergic house-dust mite rhinitis, 141
- Alpha synuclein, 322
- Aluminum neurotoxicosis, effect of PRP on, 183
- Alzheimer's disease (AD), 311, 319, 321
 - β -amyloid proteolytic product (A β), 230
 - astrogliosis, 402
 - atypical microglial activation, 402
 - cytokines, 402
 - model of, effect PRP on, 183
 - presenilin 2 (PS2), 230
 - proteasome inhibition, 230
 - treatment, 402
- Amyloid beta (A β), 316
- Amyloid plaque, 321
- Amyloid precursor protein, 320
- Amyotrophic lateral sclerosis, 323
- Anaphylactic shock, 133, 139
- Angiotensin II, 441
- Animal models, 139
- Antibody(ies), 383–387
 - production in the brain of, 168
- Antibody-mediated remyelination, 341, 342
- Antigen presentation, 313
- Antigen presenting cell (APCs), 270, 313, 335
- Antigen-presenting cells in CNS antigens
 - astrocytes, 208, 209
 - microglia, 206–209
 - perivascular space, 207, 208
 - T cell activation, 207
- Anti-inflammatory cytokines
 - interleukin 10 (IL-10), 206
 - transforming growth factor β (TGF- β), 206
- Anti-KLH antibody responses, 74, 75
- Antineuronal antibodies, 338
- Apoptosis, 64, 67, 68, 434
- Apoptosis inducing factor, 428, 431, 433, 438, 451
- Arthritis, 134, 139
 - adjuvant-induced arthritis, 85, 86
 - rheumatoid arthritis, 85, 97, 109
- Aspartate, 45, 47
- Asthma-like symptoms, 139
- Asthmatic patients, 139
- Astrocytes, 236, 237, 241–244, 246, 247, 249–255, 313–318, 430, 446, 450
- ATP
 - intracellular levels of, 446
- Atrophy, brain, 389
- Autoantibodies in schizophrenia, 473, 474
- Autoimmune, 381–388
- Autoimmune disease(s), 337, 342
 - lupus, 20, 21
 - RA, 20–23, 25, 27
 - stress and, 85–87, 90, 91, 95, 96, 98, 101, 106, 111
 - sympathetic regulation of, 86
- Autoimmune etiology, 342
- Autoimmune illnesses
 - antiphospholipid syndrome, 469
 - coeliac disease, 469
 - increased risk of schizophrenia with, 471
 - insulin dependent diabetes mellitus (IDDM), 469
 - rheumatoid arthritis, 469–471
 - Sydenham's chorea, 469
 - systemic lupus erythematosus (SLE), 469, 471, 473
 - thyrotoxicosis, 470
- Autoimmunity, 237
- Autonomic nervous system
 - cholinergic anti-inflammatory pathway, 302
 - immune system modulation by stress, 298, 299
 - non-neuronal cholinergic system, 303
 - sympathetic nervous system, 85, 97, 103
 - vagal nerve, 301–303
- Autoreactive antibodies, 341
- AVP
 - co-localisation of CRF with, 23
 - inflammatory effects of, 23
 - receptors, 23
- Axonal injury, 389
- B cells, 238–240, 252, 253
- B Lymphocytes, 68, 69, 72
- Backward association, 131
- Bacteria, 38, 39, 41, 49

- BDNF. *See* Brain-derived neurotrophic factor
- Behavior, 38, 45, 47, 49–52
- Biobreeding (BB), 336
- Blood-Brain barrier (BBB), 335, 346, 472, 474
- circumventricular organs, 201
 - components of, 372
 - functions of, 372
 - in EAE, 371, 372
 - loss of integrity, 373
 - neurotransmitter release, 303
 - neurovascular unit, 200–203
 - open areas, 295, 298
 - permeability in inflammation, 295
 - platelet-endothelial cell adhesion molecule1, PECAM-1, CD31, 201
 - pro-inflammatory mediators:
 - IL-1, IL-6, IFN- γ , TNF- α , 198
 - tight junctions, 200
 - transendothelial electrical resistance (TEER), 203–204
 - virchow-robin spaces, 201, 204
 - zonula occludens molecules, 201
- Bone marrow, 63–65
- Bordetella pertussis, 339
- Borrelia burgdorferi, 338
- Brain
- antibody production in, 168
 - neuroendocrine immune system of, 175–178, 183
- Brain cytokines
- alzheimer's disease, 302
 - changes in psychiatric disorders, 301
 - enhance sleep, 300
 - expressed in brain, 300
 - glucocorticoid suppression, 301
 - modulate body temperature, 300
 - penetrate blood brain barrier, 301
- Brain-derived neurotrophic factor, 265
- Brain function
- cytokines administration of, 6, 7
 - effect of, 7
- Brain-to-immune pathway, 125
- Brown Norway (BN) strains, 341
- Bystander activation, 387
- Catalase, 71
- Catecholamines, 93. *See also* norepinephrine and epinephrine regulation of tumor necrosis factor alpha
- dopamine, 41
 - MHPG, 41
 - norepinephrine, 41, 42
- CD3, 64, 67
- CD4, 64, 65, 67, 68, 73, 74
- CD40 ligand, 315, 316
- CD8, 64, 65, 67, 68, 73
- Cell-mediated immune reactions
- against autoantigens (CMAI), 336
- Cellular infiltration, 340
- Central nervous system (CNS)
- immunological reactivity in, 335
 - immunosuppression in, 336
 - infectious agents in, 336
 - mechanism of autoimmunity in, 336
 - virus-induced damage to, 337
- Cerebrospinal fluid (CSF), 338
- Cerebrovascular endothelial cells (CVE), 343
- Chemical sympathectomy, 64, 65, 67, 69, 73
- Chemokines, 316, 318, 325, 326, 440, 447, 451
- classification of, 164–166
 - fractalkine, 412, 413
 - interleukin-8 (IL-8), 413
 - MCP-1, 413
 - MIP-1 α , 411, 413, 417
 - MIP-1 β , 411, 413, 417
 - RANTES, 411, 417
 - receptors of, 166, 167
 - role in neurons of, 167, 168
- Chemotherapy, 140
- Chronic β -adrenergic receptor blockade, 67, 68
- Chronic inflammatory demyelinating neuropathy, 380
- Ciliary neurotrophic factor (CNTF), 265
- Circumventricular organs, 125
- Classical conditioning, 125, 129
- CNS-immune communication, 131
- Compensatory conditioned effects, 132
- Complement system
- glial localization, 296
 - neurodegeneration, 296
 - viral and bacterial infections, 296
- Concanavalin A (Con A), 62, 71, 74
- Conditioned not re-exposed, 137, 141
- Consciousness, 132
- Contact hypersensitivity reaction, 139
- Contingency, 131
- Cortical thymic epithelium, 336
- Corticosterone, 39, 40, 42, 44–46, 48–50
- Corticotropin releasing factor (CRF), 38, 44, 48–50
- Corticotropin releasing hormone, 87
- Coxsackievirus-adenovirus receptor (CAR), 267
- Creutzfeldt-Jakob disease, 325
- CRF family of peptides
- AA, 21
 - CRF (1–41), 21–23
 - EAE, 21
 - heterogeneity in human T cells of, 21, 22
 - human PBMC, 21, 22
 - inflammatory effects of, 21
 - R1 and R2 receptors, 21, 23
 - rat splenocyte contents of, 21, 22
 - substance P and, 22
 - urocortins 1, 2 and 3, 22, 23
- CS / US administration route, 133
- Cyclic adenosine monophosphate (cAMP), 66, 74, 75
- 2', 3'-Cyclic Nucleotide 3' Phosphodiesterase (CNPase), 384
- Cyclooxygenase, 38, 49, 51
- Cytokine mRNA expression, 10
- Cytokine receptors and production in brain, 6
- Cytokines, 88, 91–94, 96–98, 103, 105–111
- action locality of, 160
 - antipsychotic effects on, 480
 - brain born, 155, 164, 176
 - brain receptors of, 164
 - cytokine releaser polyribonucleic-polyribocytidilic acid (poly I: C), 472
 - cytokine system, superfluity of, 160–163
 - cytokines in neuromodulation, 474
 - granulocyte-macrophage colony-stimulating factor (GM-CSF), 38, 47
 - induction of, 159, 161, 163
 - interferon- α , 476
 - interferon (IFN)- γ , 315, 384, 386, 411, 412, 415, 416, 419, 472
 - interleukin-1 (IL-1), 38, 39, 41, 42, 315, 380, 413
 - interleukin-1 β , 472
 - interleukin-1RA, 475
 - interleukin-2, 38, 45, 472, 476
 - interleukin-4, 417
 - interleukin-6, 38, 45, 472, 476
 - interleukin-8, 472, 477, 480
 - interleukin-10, 475, 479, 480
 - interrelationship and interdependency of, 163
 - neurosecretion of, 176
 - recombinant interleukin-2, 475, 476

- tumour necrosis factor – α , 38, 315, 318, 323, 386, 409, 412, 415–417, 419, 472, 475, 477, 480, 481
- Cytokines antiinflammatory, 6
- Cytotoxic T cells (CTLs), 270, 344
- Delayed-type hypersensitivity (DTH), 134, 137, 335
- Demyelination, 380–389
- Dendritic cells (DCs), 386
 - CCR2 and CCR5, 210
 - DC-SIGN (CD209), 210
 - FMS-like tyrosine kinase 3 ligand (Flt-3L), 210
 - granulocyte-macrophage colony-stimulating factor (GM-CSF), 209
 - interleukin 17 (IL 17), 210
 - plasmacytoid DCs, 210
 - tissue localization, 209
- Depression, 47, 51, 52
- Dermatitis, 139
- Devic's disease, 339
- Differential peptide processing
 - CRF, 21–23
 - POMC, 23, 24
 - post-translational modification, 29
- Differentiation of pre-T cells, 64
- Disseminated intravascular coagulation (DIC), 268
- Dopamine, 321, 322
- Dopamine- β -hydroxylase, 67
- Dual (Double) negative, 62, 64
- Dual (Double) positive, 62, 64
- Encephalitis lethargica (EL), 340
- Endogenous pyrogens, 7, 8
- β -Endorphin therapeutic genes, 267
- Endothelial cells, 444, 446, 447
- Endotoxin (Lipopolysaccharide, LPS), 38
- Engram specificity, 133
- Enzymes
 - cyclooxygenase-2 (COX-2), 418
 - granulocyte macrophage colony-stimulating factor (GM-CSF), 417
 - inducible nitric oxide synthase (iNOS), 417
 - nitric oxide (NO), 417
 - platelet activating factor (PAF), 419
 - prostaglandin E₂ (PGE₂), 419
 - quinolinic acid (QUIN), 149
- Epinephrine, 85, 92
- Epitope spreading, 388
- Epstein-Barr virus infections, 343
- Excitotoxicity, 319
- Experimental autoimmune encephalomyelitis (EAE), 336, 343, 381
 - history, 357
 - immunopathology of, 361–370
 - innate immune system in, 370, 371
 - in non-human primates, 360
 - models of, 358–361
 - pathology of EAE
 - in guinea pig model, 361
 - in Lewis rat model, 362
 - in mouse model, 361
 - in rodents, 359, 360
 - toll like receptors in, 370
- Experimental groups, 141
- Extinction, 127, 130, 131, 133, 139, 142
- Familial amyotrophic lateral sclerosis (ALS)
 - impaired immunoproteasome function, 231
 - intracellular inclusions, 231
 - SOD 1 mutations, 231
- Fenton reaction, 322
- Fractalkine, 316
- Free radicals (ROS), 70
- Gamma-aminobutyric acid (GABA), 44, 45, 47, 340
- GDNF. *See* Glial-derived neurotrophic factor
- Gender, 132, 142
- Gene therapy for pain, 266, 267
- Gene therapy vectors, 267
- GFAP. *See* Glial fibrillary acidic protein
- Glia, 309–312, 321–323
- Glial-derived neurotrophic factor, 265
- Glial fibrillary acidic protein, 265
- Glioblastoma multiforme (GBM), 266
 - INF- γ inducible subunit accumulation, 231, 232
 - programmed cell death, 231, 232
 - proteasome peptidase activity downregulation, 231, 232
- Glucocorticoids, 6, 88, 89, 94, 111
- Glucose homeostasis, 8
- Glutamate, 44, 45, 47, 319, 324
- Glutamic acid decarboxylase (GAD), 340
- Group A streptococcus (GAS), 338
- Guillain Barre Syndrome, 337, 380, 387
- Heart
 - neurosecretory hypothalamus-endocrine heart system, 156, 157
- Heart allografts, 139
- Heat shock proteins, 313
- Herpes simplex virus infection, 347
- HIV
 - infection of astrocytes, 410
 - infection of microglia, 411
 - infection of neurons, 410
 - life cycle, 408
- HIV associated dementia, 408–419
- HIV encephalitis, 325
- HLA antigens
 - genetic linkage, 471
 - HLA-A1 as predictor of granulocytosis on clozapine treatment, 471
 - maternal antibody to fetal HLA, 471
 - response to treatment, 471
- Hormones
 - immune suppression and facilitation, 299
 - interactions of stress response with immune system, 299
- HPA axis, 38–40, 44, 48, 50–52, 125, 138
- Human studies, 139–141
- Humoral CNS-immune communication, 131, 142
- Huntington's disease (HD), 265
 - CAG triplet expansion (huntingtin), 231
 - immunoproteasome expression increase, 231
 - proteasome peptidase activity modulation, 231
- 6-Hydroxydopamine, 62, 64, 85
- Hyperphosphorylated tau, 320
- Hypothalamo-pituitary-adrenocortical (HPA) axis. *See* HPA axis
- Hypothalamus
 - magnocellular nuclei of, 156, 157
 - neurosecretory hypothalamus-endocrine heart system, 156, 157
- Hypoxanthine-guanine phosphoribosyltransferase (HPRT) activity, 265
- IL1 β
 - epileptic activity reduced by IL1 α , 296
 - epilepsy enhanced by IL1 β , 296
- Immune cytokines
 - brain-controlled homeostatic mechanisms and, 7–9
 - induction and relevance of
 - neuronal signals and, 10
 - peripheral immune signals, 9, 10
 - integrative role of, 13
 - and thermoregulation, 7
- Immune history, 132, 133

- Immune organs, sympathetic innervation in experimental arthritis, 99
- Immune privilege
– definition, 198
– lymphatic drainage, 199, 200
- Immune senescence, 62, 63, 76
- Immune synapse
– communication hot spots, 303
– criteria, 304
– integrins, 305
– prototypic synapse, 304
– scaffold, 304, 305
– supramolecular activation cluster, 305
– T cells and DC cells, 304
- Immune system, neuroendocrine, of brain, 157–159
- Immune-neuroendocrine network, 4, 5
- Immune-to-brain pathway, 124
- Immunity
– adaptive, 312, 313
– innate, 313, 317, 319, 326
- Immunological signaling molecules, 341
- Immunological status, factors contribution, 335
- Immunological synapse, 4
- Immunology of EAE
– antigen presenting cells, 367, 368
– B-cells, 368–370
– CD 8⁺, 364, 368
– chemokines, 356, 366, 367, 371
– cytokines, 356, 364, 365, 367, 370
– IL-12, 365–367
– IL-17, 356, 357, 366, 368
– IL-23, 365–367
– IL-27, 366
– epitope spreading, 368
– macrophages, 361–364
– Th-2, 357, 365
– Th-17, 357, 366
- Immunomodulators
– discovery in brain of, 168
– myelin basic protein fragments, 169, 170
– thymosin β_4 , 168, 173
- Immunophilins
– cytokine function of, 171, 172
– role in nervous system of, 172–174
- Immunosuppressors, FKBP-12, 171–173
- Indoleamines, serotonin, 47
- Infection, 38–41, 43, 49–52
- Inflammation in central nervous system, characteristics and basic features, 396
- Inflammation, 85, 87, 91, 93, 95, 97, 98, 100–102, 104, 105, 108, 110, 111, 311–322
- Inflammatory mediators, 311–313, 316, 318, 321, 322
- Innate and adaptive immunity, 247
- Innate immune response, 269–271
- Innate immunity, macrophages, 86, 88
- Innervation of lymphoid organs, 125
- Innervation of lymphoid tissue, 102
- INS-dependent diabetes mellitus (IDDM), 340
- Inside out model, 389
- Interesting transcript 15 (IT15), 265
- Interferon- α , 46, 47
- Interferon- γ , 38, 46, 47
- Interleukins, 85, 88, 92, 109
- Interstimulus delays, 131
- Interstimulus intervals, 131
- Intracellular adhesion molecule-1 (ICAM-1), 343
- Intracellular protein degradation
– in cytoplasm and nucleus, 224
– in lysosomes, 224
– pathway involved, 224, 225
– ubiquitin/proteasome/ATP dependent, 225
– ubiquitin tagged proteins, 224, 225
- Intracerebral inoculation, 341
- Iron, 322
- KLH-specific proliferation, 74
- Lambert–Eaton myasthenic syndrome, 339
- Latent inhibition, 132, 140, 141
- L-Deprenyl, 71
- Lesch-Nyhan syndrome, 265
- Lethargic encephalitis, 340
- Leukocyte, 316, 319, 324
- Lewy bodies, 321, 322
- Life-span, 132
- Lipopolysaccharide (LPS)
administration, 7, 70, 71, 311, 313
- LNS. *See* Lesch-Nyhan syndrome
- Lupus erythematosus, 139
- Lyme borreliosis, 338
- Lymphocyte functional antigen-1 (LFA-1), 343
- Lymphocytes
– B lymphocytes, 313
– infiltration, 341
– T lymphocytes, 313
- Lymphoid organs, 62–64, 67, 73, 74, 76
- Lymphoid tissue, innervation of, 102
- Macrophage migration inhibitory factor, 173, 174
- Macrophage(s), 86–94, 97, 99, 100, 102, 103, 105–107, 109–111, 236–244, 246–252, 311–313, 315–317, 325
- Magnetic resonance imaging, 380
- Magnocellular nuclei, 156, 157, 175
- Major histocompatibility complex (MHC), 335
- MAP kinase
– ERK, 317
– c-Jun N-terminal kinase (JNK), 317
– p38, 317
- Marginal zone, 68, 69, 72
- Mast cells, 347
- Matrix metalloproteases (MMP), 319
- Measles–mumps–rubella (MMR) antibodies, 337
- Mechanisms
– neural network, 133
– peripheral pathways, 124, 125
- Meningitis
– effect of PARP deficiency, 435–441
– effect of PARP inhibitors, 443–448
- α -Methylnorepinephrine, 62, 69
- 3-Methoxy-4-hydroxyphenylethylene glycol (MHPG)/NA ratio, 6
- MHC class I and II expression in brain, 272
- Microglia, 236, 237, 242–244, 246–252, 254, 255, 312–317, 380, 382, 386, 389
- Microglia cells, 335
– activated microglia, 297
– basic features, 396
– CNS macrophages, 296, 297
– in Alzheimer's disease, 402
– in Parkinson's disease, 398–400
– in prion's disease, 400–402
– resident macrophages, 296, 301
- Molecular mimicry, 387
- Monoamine oxidase B (MAO-B) inhibitor, 71
- Mouse monoclonal antibodies (mAbs), 342
- MPTP, 449, 451, 452
- Multiple sclerosis (MS), 140, 266, 312, 324, 342, 343
– as relates to EAE, 356
– effect of PARP inhibitors, 444–448
– immunomodulatory treatments of, 356
– primary progressive, 380
– relapsing remitting, 380
– secondary progressive, 380

- Mycobacterium tuberculosis, 339
 Myelin, 381–389
 - autoimmune demyelination, 356
 - peptides, 356, 358
 - proteins, 356, 359
 Myelin basic protein (MBP), 336, 383
 Myelin oligodendrocyte basic protein (MOBP), 384
 Myelin oligodendrocyte glycoprotein (MOG), 336, 383
 Myelin-producing cells, stimulation of, 342
 NAD, intracellular levels of, 432
 NADPH oxidase, 318, 322
 Natural killer cell activity, 71–73
 NE turnover, 62, 69, 70
 Necrosis, 428–432, 435, 440, 442
 Nerve growth factor (NGF), 62, 71, 72
 - in brain astrocytes, 265
 Neural CNS-immune communication, 124, 125
 Neurodegeneration
 - effect of PARP deficiency, 449
 - effect of PARP inhibitors, 448–450
 Neurodegenerative disease, 317, 319–321, 326
 Neuroendocrine autoantigen, 340
 Neuroendocrine immune system of brain, discovery of, 175–178
 Neurofibrillary tangles, 320
 Neurohormones, 156, 157, 176
 Neurohypophysis, neurosecretory granules of, 173
 Neuro-immune associative learning
 - auditory, 125, 127, 131, 133
 - conditioned, CS, 127
 - gustatory, 125, 134, 135, 142
 - olfactory, 125, 140, 142
 - recall
 - behaviorally conditioned immune effects, 130
 - conditioned, CR, 129, 130
 - response, 129, 130
 - unconditioned, UR, 141
 - touch, 125, 131
 - unconditioned stimulus, US
 - genuine / directly perceived, 129, 132
 - sham / indirectly perceived, 129
 - visual, 125, 126, 131, 133
 Neuro-inflammation, 236, 241, 242, 312, 318, 320, 323–326
 Neurological diseases treatment by gene therapy, 265, 266
 Neuromelanin, 424
 Neuromyelitis optica (NMO), 339
 Neuromyotonia (NMT), 339
 Neuronal-glia interactions, 7
 Neurons, effect of PRP (proline rich peptides) on, 181–182
 Neuropeptides
 - alpha-melanocyte-stimulating-hormone (α -MSH), 205
 - BDNF, 298
 - CGRP, 294, 298
 - communication between immune system and CNS, 298
 - neuropeptide γ (NPY), 205
 - somatostatin (SST), 205
 - substance P, 298, 299
 - VIP, 205, 298, 299, 301
 Neuropsychiatric disease, 338
 Neurosecretory hypothalamus-endocrine heart system, 156, 157
 Neurotransmitters, 39, 51
 - acetylcholine, 303
 - glutamate, 298
 - noradrenaline, 299, 302
 - serotonin, 299, 300
 Neurotrauma
 - effect of PARP deficiency, 429
 - effect of PARP inhibitors, 441–443
 Nitric oxide (NO), 318
 - as an activator of PARP, 451
 - in CNS, 432
 NMDA receptors, 319, 321
 Node of Ranvier, 381, 389
 Non-contingent conditioned, 141
 Non-POMC-derived opioid peptides
 - dynorphin, 26–28
 - endomorphins 1 and 2, 26
 - enkephalins, 26
 - involvement in inflammation, 27, 28
 - lymphocyte trafficking of, 28
 - mediation of neurogenic pain by, 27
 - nociceptin/orphanin FQ, 26, 27
 - selective delivery to inflamed tissues of, 28
 Noradrenergic innervation, 62
 Norepinephrine (NE), 62–67, 69–71, 74–76, 85, 92, 93
 Nuclear factor kappa B, 314
 1, 2',5'-Oligoadenylate synthetase (OAS), 270
 Oligoclonal bands (OCB), 338
 Oligodendrocyte(s), 318, 324, 381, 383, 386, 388, 389, 434, 439, 445
 Oligodendrocytic-specific glycoprotein (OSP), 384
 One learning trial conditioning, 131
 Oxidative stress, 322
 Parkinson's disease (PD), 266, 321–323
 - astrogliosis, 398
 - atypical microglial activation, 400
 - cytokines, 398–400
 - etiology, 398
 - proteasome proteolytic activity, 230
 - 19S reg interaction, 230
 - α -synuclein aggregates, 230
 - treatment, 399
 Partial reinforcement, 131
 Passive forgetting, 131
 Pathogen-associated molecular patterns (PAMPs), 313
 Peptidergic nerves, 63, 69
 Periarteriolar lymphatic sheath, 62, 68
 Pericyte
 - CNS antigen presenting cell, 297, 305
 - essential elements of BBB, 297
 - pathomechanisms of hypoxia, hypertension etc., 297
 Phospholipid-binding proteins, 336
 Placebo, 140, 141
 Plaque, 380, 381, 386
 Poly (ADP-ribose) glycohydrolase, 429, 431, 438, 442
 Poly (ADP-ribose) polymerases
 - and cell death, 429, 432, 442
 - and DNA repair, 429, 453
 - and neurotrauma, 435
 - and NMDA receptor activation, 432, 451
 - and stroke, 443–441
 - interactions with nuclear proteins, 451
 - isoforms, 428, 439, 443, 450
 - regulation of genes by, 428
 POMC family of peptides
 - ACTH, 23–26
 - biphasic effects of, 24
 - β -endorphin, 23–26
 - increases in response to inflammation of, 25
 - interactions with cytokines, 24, 25
 - MC receptors, 24
 - naloxone-sensitive and insensitive actions of, 25
 - opioid receptors, 24, 25
 - regulation by glucocorticoids, 26
 - Th1/Th2 cytokine balance, 25, 28
 Prion's disease, 325
 - astrogliosis, 401
 - atypical microglial activation, 401

- cytokines, 401
- treatment, 400
- Proenkephalin A, 267
- Progressive multifocal leukoencephalopathy, 388
- Proinflammatory cytokines, 88, 94, 98, 103, 105–108
- Proline rich peptides (PRP), 155, 157, 177–188
- Prostaglandin E2 (PGE2), 336
- Prostaglandins, 326
- Proteasomes, 316, 322
 - antigenic peptide generation, 227, 229
 - brain constitutive and immunoproteasomes, 226, 228, 229
 - constitutive and immunoproteasomes, 228, 229
 - hybrid proteasome, 226
 - immunoproteasome, 226–228
 - INF- γ inducible subunits, 226–228
 - peptidase activity, 225, 226
 - proteasome inhibitors, 229
 - proteolytic activity, 226
 - 20S proteasome, 225, 226
 - 26S proteasome, 225, 226
 - 11SReg–20S proteasome, 225, 226
 - 11S regulator (11S reg), 225–227
 - 19S regulator (19S reg), 225–227
- Proteasomes and neurodegenerative diseases
 - insoluble protein aggregates, 229
 - proteasome proteolytic activity depression, 230
- Proteins, gp120, 411–414
- Proteolipid protein, 383
- Proteolipid protein (PLP) isoform, 336
- PRP (proline rich peptides)
 - action after nerve transection, 181, 182
 - action in spinal cord injury, 181, 182
 - antibacterial activity of, 178, 179
 - anti-snake venom effect of, 181, 182
 - effect on aluminum neurotoxicosis of, 183
 - effect on neurons of, 183
 - effect on thymocyte differentiation of, 179, 180
 - neuroprotective (antineurodegenerative) properties of, 181–183
 - PRP-1 (proline rich peptide 1), 181
 - PRP-3 (proline rich peptide 3), 181
 - regulation of myelopoiesis by, 180
 - stimulation of bone marrow stem cells by, 180, 181
- Raf/mitogen-activated protein kinase (MAPK) pathways, 267
- Rapid eye movement, 10
- Reactive oxygen species (ROS), 318, 322, 386, 387
- Reconditioning, 142
- Red pulp, 68
- Regulatory cell surface molecules
 - FasL-FAS interactions, 206, 207
 - PD1-PDL1, 206
- Reinforcement trials, 131
- REM. *See* Rapid eye movement
- Retention, 131, 133, 139
- Rheumatoid arthritis
 - autoimmunity, 86
 - cytokines, 96–98
 - macrophages, 105–107
 - Th1/Th2 lymphocytes, 91
 - treatment of, 96
- Schistosoma mansoni, 339
- Schizophrenia, 339, 340
 - anatomical brain changes in, 469, 471
 - birth order, 471
 - clinical features and symptoms of, 468
 - etiology, 469
 - immunological changes in, 469
 - neurotransmitters in pathogenesis, 469
 - relationship to autoimmune illnesses, 469
 - rhesus incompatibility, 471
 - treatment of, 481
- Seasonal allergic rhinitis, 140
- Serum antibody levels, 75
- Severe combined immunodeficiency (SCID) mice, 72, 75
- Signal transduction, 155, 160, 162, 163, 171
- Skin grafting, 139
- Spinal cord homogenate (SCH), 342
- Spinal cord injury (SCI), 341
- Spleen, 63, 66–75
- Spleen and rheumatoid arthritis, 85, 97, 109
- Spongiform encephalopathy, 325
- Spontaneous mammary tumor growth, 71
- Stem cells, stimulation by PRP (proline rich peptides) of, 180, 181
- Stiff-man syndrome (SMS), 339–341
- Stimulus, 125, 126, 128–130, 134, 135, 140–142
- Streptococcus pyogenes, 338
- Stress, 40, 52
- Stroke
 - and vascular dysfunction, 432
 - design of preclinical studies, 434
 - effect of PARP deficiency, 435–441
 - effect of PARP inhibitors, 435–441
- Stroke, 325
- Substantia nigra, 321, 322
- Superoxide dismutase (SOD), 62, 71, 323
- Sydenham's chorea (SC), 338
- Sympathetic modulation, 73–75
- Sympathetic nerves, 65–67, 69–75
- Sympathetic nervous system, 62, 125
 - cytokines and activity of, 96–98
 - dysregulation in animal models, 95–101
 - dysregulation in rheumatoid arthritis, 95–101
 - intervention in autoimmune disease, 102
 - lymphoid tissue and innervation of, 97–99
- T-cell activation, requirement for, 335
- T-cell infiltration, 273
- T-cell receptor (TCR), 338
- T cells, 237–244, 246, 248, 250–253, 255
- T lymphocyte, 68, 69, 72
 - CD4 and CD8, and spleen, 91, 94, 99, 100, 104
 - CD4+ T lymphocytes, 380
 - CD8+ T lymphocytes, 385, 388
 - gamma delta T cells, 385
 - natural killer (NK) cells, 386
 - regulatory T lymphocytes (T reg cells), 386
 - rheumatoid arthritis, 109
 - Th1 lymphocytes, 385
 - Th1/Th2 balance and pattern, 91–93
 - Th2 lymphocytes, 384, 386
- Tau, 320, 321
- Th1 cytokine, 73, 75
- Th2 cytokine, 73, 75
- Theiler's murine encephalomyelitis virus (TMEV), 341
- Theiler's virus, 344, 345, 388
- Theiler's virus induced demyelination (TVID), 343, 344, 347
- Thymic epithelial cells, 336
- Thymic involution, 63, 65, 66
- Thymic nerves, 65, 66
- Thymocyte differentiation, 65, 67, 68

- Thymocyte proliferation, 67, 68
- Thymosin β_1
- calmodulin antagonist function of, 173
 - isolation from neurosecretory granules of neurohypophysis of, 173, 176
- TLR4 receptor
- expression on glia cells, neurons, 295
 - LPS activated, 295
- TNP-hemocyanin, 4
- Tolerance, 130, 133
- Toll-like receptors (TLR), 313, 314
- Transaldolase-H (Tal-H), 384
- Traumatic brain injury, 325
- Trichuris trichuria, 339
- Trypanosoma brucei brucei, 339
- Tryptophan, 38–40, 43–47, 49–52
- Tumor growth, 134, 139
- Tumor necrosis factor (TNF), 343
- Tumor necrosis factor-alpha (TNF- α)
- bioactivity, 6
 - catecholamine regulation of, 94, 95
- Tyrosine hydroxylase, 62, 69
- Ubiquitin, 322
- Unconditioned response, 125, 132, 141
- Unreinforced trials, 131
- Uric acid, antioxidant effects of, 444
- Vagus nerve, 49
- Vasoactive amine (VAA)
- sensitization, 347
- Viral infection
- Coxsackie B5, 471, 474
 - effect of virus-induced maternal response on fetus, 471–472
 - herpes simplex, 471, 473
 - influenza, 471–473, 479
 - rubella, 471, 473
 - viral antibodies in schizophrenia, 473
- Viruses, 39
- Vitamin B12, 380
- White pulp, 68–70